Neurocrine Biosciences, Inc. $NBIX Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 94,795 shares of the company’s stock after buying an additional 7,255 shares during the quarter. Fisher Asset Management LLC owned about 0.10% of Neurocrine Biosciences worth $13,307,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Geneos Wealth Management Inc. raised its holdings in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. Golden State Wealth Management LLC boosted its position in Neurocrine Biosciences by 120.5% in the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after buying an additional 100 shares during the period. Eastern Bank acquired a new position in Neurocrine Biosciences during the 3rd quarter worth $27,000. Quent Capital LLC acquired a new position in shares of Neurocrine Biosciences during the third quarter worth about $32,000. Finally, MAI Capital Management increased its position in shares of Neurocrine Biosciences by 101.2% in the 2nd quarter. MAI Capital Management now owns 328 shares of the company’s stock valued at $41,000 after purchasing an additional 165 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. UBS Group cut their target price on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Wells Fargo & Company reduced their target price on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Citigroup upped their price objective on shares of Neurocrine Biosciences from $203.00 to $204.00 and gave the stock a “buy” rating in a research report on Thursday, February 12th. Wall Street Zen cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Monday, February 16th. Finally, Wedbush boosted their price objective on shares of Neurocrine Biosciences from $149.00 to $151.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $175.05.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $133.44 on Thursday. The firm’s 50 day moving average price is $135.00 and its 200 day moving average price is $140.52. The firm has a market cap of $13.39 billion, a P/E ratio of 28.64, a price-to-earnings-growth ratio of 0.68 and a beta of 0.32. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). The business had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.Neurocrine Biosciences’s revenue for the quarter was up 28.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.69 EPS. As a group, equities analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Insider Activity

In other news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares of the company’s stock, valued at $18,632,008.90. This represents a 20.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Darin Lippoldt sold 4,376 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $159.65, for a total transaction of $698,628.40. Following the completion of the sale, the insider owned 43,405 shares of the company’s stock, valued at approximately $6,929,608.25. The trade was a 9.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 46,966 shares of company stock valued at $6,474,616 in the last 90 days. 4.80% of the stock is currently owned by insiders.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.